Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) EBIT: 2010-2024

Historic EBIT for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$103.2 million.

  • Altimmune's EBIT rose 15.78% to -$20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.5 million, marking a year-over-year increase of 19.18%. This contributed to the annual value of -$103.2 million for FY2024, which is 7.55% down from last year.
  • According to the latest figures from FY2024, Altimmune's EBIT is -$103.2 million, which was down 7.55% from -$95.9 million recorded in FY2023.
  • In the past 5 years, Altimmune's EBIT ranged from a high of -$54.8 million in FY2020 and a low of -$103.2 million during FY2024.
  • For the 3-year period, Altimmune's EBIT averaged around -$95.6 million, with its median value being -$95.9 million (2023).
  • Per our database at Business Quant, Altimmune's EBIT slumped by 155.29% in 2020 and then climbed by 9.47% in 2022.
  • Yearly analysis of 5 years shows Altimmune's EBIT stood at -$54.8 million in 2020, then slumped by 76.85% to -$96.9 million in 2021, then rose by 9.47% to -$87.7 million in 2022, then fell by 9.33% to -$95.9 million in 2023, then decreased by 7.55% to -$103.2 million in 2024.